Abstracts tagged "Eye Disorders"

Abstract Number: 0159 • ACR Convergence 2023
Understanding the Economic Impact of Autoimmune Eye Disease in the United States
Krati Chauhan¹, Steven Scaife² and Michael Buhnerkempe¹, ¹Southern Illinois University - School of Medicine, Springfield, IL, ²Southen Illinois University - School of Medicine., Springfield, IL
Background/Purpose: Eye involvement is an important cause of morbidity in rheumatology patients. Inflammatory eye diseases include conditions like scleritis, uveitis, retinitis and orbital inflammation. The…
Abstract Number: 2042 • ACR Convergence 2023
Intraocular Cytokine Profiling of Autoimmune Uveitis
Maryrose Hahn¹, Madison Mangin², Marc Todd¹, Pui Lee¹, Mindy Lo¹, Bharti Gangwani³, Ankoor Shah³, Amanda Colombo⁴, Jessica Scott⁴, Stephen Anesi⁴, C. Stephen Foster⁴, Peter Chang⁴, Peter Nigrovic² and Margaret Chang², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Department of Ophthalmology, Boston Children's Hospital, Boston, MA, ⁴Massachusetts Eye Research and Surgery Institution, Waltham, MA
Background/Purpose: Autoimmune uveitis is an inflammatory disorder of the eye that is associated with significant morbidity, including vision-threatening complications and chronic reliance on immunosuppressive therapies.…
Abstract Number: 0263 • ACR Convergence 2023
Patient, Disease, and Treatment Factors in Remission of Inflammatory Eye Disease
Taylor Koenig¹, David Fell¹, Danny Mammo¹, Chao Zhang², Sunil Srivastava¹, Careen Lowder¹, Sumit Sharma¹ and Rula Hajj-Ali¹, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Noninfectious inflammatory eye disease (NIIED) is a sight-threatening condition with two-thirds of patients incurring prolonged vision loss due to uncontrolled ocular inflammation. Non-glucocorticoid systemic…
Abstract Number: 2045 • ACR Convergence 2023
Treatment Response in a Cohort of Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)
Ilaria Maccora¹, Arjun Sood², Grant Schulert³, Alexandra Duell³, Preston Land⁴, Cameron C Sapp², Jennifer Huggins³, Tiffany Nguyen², Megan Quilan-Waters³, Sumit Sharma⁵, Sunil Srivastava² and Sheila Angeles-Han⁶, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Cincinnati Eye Institute, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Medical Center, Cincinnati, OH, ⁵Cleveland Clinic, Cleveland, OH, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Pediatric uveitis often requires systemic immunomodulatory therapy (IMT) to prevent sight-threatening complications. Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is a rare autoimmune condition caused…
Abstract Number: 0280 • ACR Convergence 2023
Immunosuppression in the Treatment of Susac Syndrome: A Retrospective Evaluation of the Largest Cohort of Susac Syndrome
Adam Brown¹, Robert Rennebohm², Ghulam Abbas Kharal², Devon Conway², Sunil Srivastava³, Sumit Sharma², Careen Lowder², Leonard Calabrese⁴ and Rula Hajj-Ali², ¹Cleveland Clinic Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cincinnati Eye Institute, Cincinnati, OH, ⁴Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Susac Syndrome is a rare autoimmune condition causing microvascular occlusions in the brain, retina and inner ear leading to the characteristic triad of encephalopathy,…
Abstract Number: 2054 • ACR Convergence 2023
Superiority of Adalimumab in Treating Childhood Chronic Idiopathic Uveitis: Evidence from a Multicentre Experience
Ilaria Maccora¹, Catherine Guly², Lavinia Sanfilippo³, sara Soldovieri⁴, Cinzia De Libero⁵, Athimalaipet V Ramanan⁶ and Gabriele Simonini⁷, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Ophthalmology Unit, Bristol Eye Hospital, Bristol, United Kingdom, ³Meyer Children's Hospital IRCCC, Florence, Italy, ⁴Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence, Italy, ⁵Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, ⁶Bristol Royal Hospital for Children & Translational Health Sciences, University of Bristol, Bristol, United Kingdom, ⁷Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: Childhood Chronic Idiopathic Uveitis (cCIU) is a severe ocular condition that accounts for the 40% of all uveitis in children. Its timely and proper…
Abstract Number: 0361 • ACR Convergence 2023
Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience
Leah Medrano and Alice Hoftman, David Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: There is limited data on pediatric golimumab dose escalation, with some data available only in the adult literature. The subcutaneous formulation is not approved…
Abstract Number: 2452 • ACR Convergence 2023
Assessment of Association Between Hydroxychloroquine Use and Toxic Retinopathy, Overall and by Indication, in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System
Rachel Robbins¹, Toni Rush² and Jess Edison³, ¹Walter Reed National Military Medical Center, Germantown, MD, ²Health Research Tx, Pace, FL, ³Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD
Background/Purpose: While generally believed to be a safe, well-established treatment, hydroxychloroquine (HCQ) use is associated with irreversible retinal toxicity requiring regular monitoring. The objective of…
Abstract Number: 0373 • ACR Convergence 2023
Potential Tear-Based Uveitis Biomarkers in Children with JIA: A Pilot Study
Ilaria Maccora¹, Mekibib Altaye², Tiffany Nguyen³, Kenneth Greis⁴, Wendy Haffey⁴, Theresa Hennard⁵, Alyssa Sproles², Sherry Thornton², Virginia Miraldi Utz⁵ and Sheila Angeles-Han², ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Eye Institute, Cincinnati, OH, ⁴University of Cincinnati, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Children with oligoarticular JIA are at increased risk of developing uveitis. JIA category, ANA positivity, ≤4 years JIA duration, and < 6 years old…
Abstract Number: 2474 • ACR Convergence 2023
Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience
Ilaria Maccora¹, Valerio Accardo², Marco Cattalini³, ilaria Pagnini⁴, Andrea Taddio⁵, Edoardo Marrani⁶, francesco La Torre⁷, Matteo Trevisan⁸, Maria Vincenza Mastrolia⁹ and Gabriele Simonini¹⁰, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²University of Florence, Florence, Italy, ³Spedali Civili di Brescia, Brescia, Italy, ⁴Meyer Children's Hospital IRCCS, Florence, Italy, ⁵Rheumatology Unit, IRCCS Burlo Garofalo, Trieste, Italy, ⁶University of Florence, Firenze, Italy, ⁷Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy, ⁸IRCCS Burlo Garofalo, Trieste, Italy, ⁹NEUROFARBA Department, University of Florence, Florence, Italy, ¹⁰Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: TNF inhibitors (TNFi) have dramatically changed the prognosis of Juvenile Idiopathic Arthritis (JIA). However, once achieved disease remission, it is not clear how and…
Abstract Number: 0501 • ACR Convergence 2023
Multicentre Study of Uveitis in Spondyloarthritis: Prevalence, Characteristics, and Prognosis
Nikolaos Kougkas¹, Konstantina Magiouf², Chrysoula Gialouri³, Gerasimos Evangelatos⁴, Maria Pappa², Afroditi Mpitouli⁵, Alexios Iliopoulos⁶, Theodoros Dimitroulas⁷, Anastasios Karamanakos⁸, Aikaterini Dimouli⁸, Maria Tektonidou², Petros Sfikakis⁹ and George Fragoulis¹⁰, ¹4th Internal Department, Ippokratio Hospital, Aristotle University of Thesaaloniki, Thessaloniki, Greece, ²Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³National and Kapodistrian University of Athens, Zografou, Greece, ⁴Rheumatology Department, 417 Army Share Found Hospital (NIMTS), Athens, Greece, ⁵Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, ⁶NIMTS Veterans Hospital, Zografou, Greece, ⁷Aristotle University of Thessaloniki - School of Medicine, Thessaloniki, Greece, ⁸“Evangelismos” General Hospital, Rheumatology Department, Athens, Greece, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, ¹⁰"Laiko" Hospital - First Department of Propaedeutic and Internal Medicine, Athens, Greece
Background/Purpose: Data are still scarce about risk factors predicting the occurrence and course of uveitis in spondyloarthritis (SpA). We aimed to examine associations between demographic,…
Abstract Number: 2548 • ACR Convergence 2023
Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Martin Rudwaleit¹, Matthew A. Brown², Floris Van Gaalen³, Nigil Haroon⁴, Lianne Gensler⁵, Carmen Fleurinck⁶, Alexander Marten⁷, Ute Massow⁸, Natasha De Peyrecave⁹, Thomas Vaux¹⁰, Katy White¹⁰, Atul Deodhar¹¹ and Irene van der Horst-Bruinsma¹², ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Genomics England, London, United Kingdom, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada, ⁵University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁶UCB Pharma, Oosterzele, Belgium, ⁷UCB Pharma, Monheim, Germany, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ¹²Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands
Background/Purpose: Acute anterior uveitis ('uveitis'), or 'iritis', is a common extra-musculoskeletal manifestation among patients (pts) with axial spondyloarthritis (axSpA).1 IL-17 has been implicated in the…
Abstract Number: 0524 • ACR Convergence 2023
Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
Nigil Haroon¹, Zeynep Baskurt², Tina Chim³, Robert Inman⁴, Diana Paez⁵, Thomas Kumke⁶, Rachel Tham⁷, Mindy Kim⁸, Irene van der Horst-Bruinsma⁹ and Lianne Gensler¹⁰, ¹University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada, ²Department of Biostatistics, University Health Network, Toronto, ON, Canada, ³University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of California San Francisco, Department of Medicine/Rheumatology, San Francisco, CA, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Atlanta, GA, ⁹Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands, ¹⁰University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting more than a third of patients. However, long-term interventional…
Abstract Number: 2550 • ACR Convergence 2023
The Incidence of Uveitis in Patients with Axial Spondylarthritis Treated with Biologics or Targeted Synthetics: A Systematic Review and Network Meta-analysis
Zijing Yang¹, Maryam Adas¹, Bechman Katie¹, Deepak Nagra¹, Ali Soykan Uguzlar¹, Mark Russell¹, Nicky Wilson², Sophia Steer¹, Sam Norton¹ and James Galloway¹, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: Anterior uveitis (AU) is one of the commonly observed extraspinal manifestations in Axial spondyloarthritis (AxSpA). Data on the protective effects of targeted immunomodulatory therapies…
Abstract Number: 1062 • ACR Convergence 2023
Antiretinal Autoantibodies in Hydroxychloroquine Eye Toxicity
Samuel Good¹, Grazyna Adamus², Michael Gorin³, Jordan Jacquez¹, Jennifer Grossman¹, Brian Skaggs¹, Ashira Hasan² and Maureen McMahon⁴, ¹University of California Los Angeles, Los Angeles, CA, ²Oregon Health & Science University, Portland, OR, ³Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Autoimmune retinopathy (AIR) is a disease process in which circulating autoantibodies (AAbs) against retina-specific antigens cause local inflammation and can lead to blindness. Hydroxychloroquine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.